io
the 10% was a somewhat arbitrary # to begin with. the real key is will nm-283 add 10% or so to SVR..based on a very pronounced effect on early viral kinetics (4 weeks), the potential to boost SVR by 10+% is quite real despite the 5% improvement on an ITT basis at 12 weeks given what we know about the relapse rate for patients who are PCR + at 4 weeks but then clear at 12 weeks compared to patients who are negaive at both timepoints..that is, a higher proportion of the cleared pateints SHOULD SVR in the nm-arm compared with the SOC arm based on everything we know about viral kinetics as predictive markers of SVR
so you could read between the lines of this press release in many different ways given the early clearance was MUCH better on triple therapy
the key also was to see if i tmerits further testing in combination with ribavirin, and the additive nature of the response is indicative that it should, and for assessing a drug interaction the on treatment statistics are the relevent statistics in this case, as teh PRIMARY purpose was not to compare a real-world outcome per se but simply to assess if there is a negative interaction or not clinically
News 
Market Data 
Discover 
